13F filer · CIK 1812549
RiverVest Venture Management LLC
St. Louis, MO · filing since Q4 2020 · last filing Oct 30, 2024
Reported value
$6.8M
+$13.2K vs prior
Positions
3
New / sold out
0 / 1
Added / reduced
0 / 0
Turnover
0.0%
buys $0 · sells $112.3K
Top-10 weight
100.0%
Biggest buys vs Q2 2024
No new or increased positions this quarter.
Biggest sells vs Q2 2024
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | Vapotherm, Inc. | -52,881 | -100.0% | $-112.3K |
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q3 2024
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | Reneo Pharmaceuticals, Inc.COMMON | 2,534,220 | $4.3M | 63.00% |
| 2 | Spruce Bioscience, Inc.COMMON | 2,936,281 | $1.4M | 20.39% |
| 3 | Xilio Therapeutics, Inc.COMMON | 1,441,444 | $1.1M | 16.60% |